Clinical trials: Severe Persistent Asthma
Asthma
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose…
- Trial name
- ADERE (Ped) (NCT01476059)
- Testing
- Telephone follow-up, No telephone follow-up
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis, Asthma
An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
The primary objective of this study is to explore the efficacy of Nasonex (mometasone furoate nasal spray) in comparison with placebo in improving the quality of life of subjects with moderate to severe persistent allergic…
- Trial name
- NCT00599027
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 51 people
- Sponsor
- Organon and Co
Asthma
Study to Evaluate the Safety and Efficacy of CAT-354
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled…
- Trial name
- NCT00873860
- Testing
- CAT-354 150 mg, CAT-354 300 mg, CAT-354 600 mg
- Where
- 57 sites in Bulgaria, Germany and 3 more
- Volunteers
- 357 people
- Sponsor
- MedImmune LLC
Asthma, Asthma Severe Persistent Uncontrolled
Severe/Uncontrolled Asthma From General Population to Clinical Setting: Update and Follow-up of the RItA Registry
Within the AGAVE project (2010-2014), funded by the 2008 AIFA (Italian Medicines Agency) Call (contract No. FARM8YRYZC), a severe/uncontrolled asthma online Registry (RItA) was implemented to assess the appropriateness of…
- Trial name
- RISER (NCT05114447)
- Testing
- Routine medical care, Telephone interview
- Where
- 4 sites in Italy
- Volunteers
- 422 people
- Sponsor
- University of Pisa
Severe Persistent Asthma
Inhaled Steroids and Control of Severe Asthma
Investigational device: AKITA 2 device versus conventional metered-dose inhaler (MDI) Objectives: To explore if inhalative fluticasone application by means of the AKITA technology would result in a better symptom control in…
- Trial name
- INHALE (NCT01197482)
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- University of Giessen
Severe Asthma
Bronchial Thermoplasty in Severe Persistent Asthma
As Conditions of Approval of the PMA for the Alair System, the FDA requires Boston Scientific to generate data to assess the durability of the BT treatment effect as well as safety data in the intended use population in the…
- Trial name
- PAS2 (NCT01350336)
- Testing
- Alair System
- Where
- 27 sites in United States, Canada
- Volunteers
- 284 people
- Sponsor
- Boston Scientific Corporation
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Asthma
Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
- Trial name
- NCT00096616
- Testing
- Combivent® CFC MDI, Albuterol HFA MDI
- Where
- 27 sites in United States
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Moderate to Severe Persistent Bronchial Asthma
Controller Medications in the Management of Bronchial Asthma
The purpose of this study is to know the effect of another controller medication add on to the inhaled corticosteroid and long acting β2 agonist on clinical symptom, lung function and compliance in patients of moderate to severe…
- Trial name
- NCT01055041
- Testing
- inhaled budesonide and formeterol plus oral montelukast, inhaled budesonide and formeterol plus oral doxophylline, Doubling the dose of inhaled budesonide and formeterol
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Government Medical College, Bhavnagar